drugset / Trial / NCT05305560

A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention

NCT05305560

Phase 2 Completed 400 enrolled MedinCell S.A Violaine Desort-Hénin, DVM · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis

Timeline

Start
2022-03-25
Primary completion
2022-09-15
Completion
2022-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 100 ug/kg Oral

Indications